TuHURA Biosciences Receives FDA Orphan Drug Designation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 02 2026
0mins
Should l Buy HURA?
Source: Newsfilter
- Orphan Drug Designation: TuHURA Biosciences' IFx-2.0 has received FDA Orphan Drug Designation for treating stage IIB to IV cutaneous melanoma, indicating the potential of new therapies in cancer immunotherapy and addressing the urgent market need for innovative treatment options.
- Clinical Trial Results: The previous Phase 1 study of IFx-2.0 demonstrated safety with no serious dose-limiting toxicities, and patients who were refractory to anti-PD-1 therapy showed clinical benefits upon subsequent treatment, highlighting its promising application in treating resistant melanoma.
- Market Exclusivity Advantage: With the Orphan Drug Designation, IFx-2.0 will enjoy seven years of market exclusivity, and the increased engagement from the FDA is expected to accelerate its development process, potentially leading to significant commercial benefits for the company.
- Future Development Focus: TuHURA is currently focused on the Phase 3 study of IFx-2.0 in combination with Keytruda® for the first-line treatment of advanced or metastatic Merkel Cell Carcinoma, aiming to provide new treatment options and further solidify its position in the oncology immunotherapy space.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HURA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HURA
Wall Street analysts forecast HURA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.800
Low
8.00
Averages
9.00
High
10.00
Current: 1.800
Low
8.00
Averages
9.00
High
10.00
About HURA
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. It is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. It is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TuHURA Biosciences Regains Nasdaq Compliance
- Compliance Regained: TuHURA Biosciences announced on February 26, 2026, that it has regained compliance with Nasdaq's listing standards, with its stock closing above $1.00 for the last 11 consecutive trading days, enhancing the company's market stability and investor confidence.
- Clinical Trial Progress: The company is advancing its Phase 3 accelerated approval trial for IFX-2.0 targeting front-line Merkel Cell Carcinoma, demonstrating its ongoing innovation in the cancer immunotherapy sector.
- New Drug Development: TuHURA is preparing for the initiation of a Phase 2 study for TBS-2025, a VISTA inhibiting antibody aimed at treating relapsed/refractory NPM1 mutated AML, further enriching its product pipeline.
- Technological Innovation: The company is also developing first-in-class bi-specific antibody drug conjugates leveraging Delta Opioid Receptor technology to inhibit immune-suppressing effects in the tumor microenvironment, thereby enhancing the efficacy of immunotherapy.
See More
TuHURA Biosciences Regains Nasdaq Compliance
- Compliance Regained: TuHURA Biosciences announced on February 26, 2026, that it has regained compliance with Nasdaq's minimum bid price requirement of $1.00, as the company's stock price remained above this threshold for 11 consecutive business days, thereby alleviating compliance concerns and boosting investor confidence.
- Clinical Trial Progress: The company is advancing its Phase 3 accelerated approval trial for IFX-2.0 in front-line Merkel Cell Carcinoma, indicating ongoing commitment to cancer immunotherapy and potential market opportunities.
- New Drug Development: TuHURA is preparing to initiate a Phase 2 study for TBS-2025 targeting relapsed/refractory NPM1 mutated AML, further diversifying its product pipeline and enhancing competitive positioning in the oncology market.
- Technological Innovation: The company is developing first-in-class bi-specific antibody drug conjugates aimed at inhibiting immune-suppressing cells in the tumor microenvironment to prevent T cell exhaustion and acquired resistance, showcasing its innovative potential in immuno-oncology.
See More
TuHURA Biosciences to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: TuHURA's CEO, James Bianco, will participate in the Citizens Life Science Conference on March 10, 2026, where he will present online, likely increasing investor interest and enhancing the company's visibility.
- One-on-One Investor Meetings: At the Leerink Global Healthcare Conference on March 11, 2026, TuHURA will offer one-on-one meetings with investors, which will help strengthen relationships with potential investors and drive funding opportunities.
- Clinical Trial Progress: TuHURA is conducting a Phase 3 registration trial for IFx-2.0 as an adjunct therapy to Keytruda, aimed at overcoming primary resistance to cancer immunotherapy, which, if successful, will significantly enhance the company's competitive position in the oncology market.
- Technological Innovation and Acquisition: TuHURA acquired TBS-2025 through its merger with Kineta Inc., which is moving into Phase 2 development, showcasing the company's innovative capabilities and potential for market expansion in immuno-oncology.
See More
TuHURA Biosciences to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: TuHURA Biosciences CEO James Bianco will participate in the Citizens Life Science Conference on March 10, 2026, and the Leerink Global Healthcare Conference on March 11, showcasing the company's advancements in cancer immunotherapy, which is expected to attract potential investors' interest.
- Clinical Trial Progress: TuHURA is conducting a Phase 3 registration trial for IFx-2.0, designed to be used in conjunction with Keytruda® for advanced or metastatic Merkel Cell Carcinoma, and if successful, it will significantly enhance the company's competitiveness in the cancer treatment market.
- Technological Innovation: The company is advancing TBS-2025, an antibody drug targeting mutNPM1 relapsed/refractory acute myeloid leukemia, into Phase 2 development, which, if successful, will further enrich TuHURA's product pipeline and strengthen its market position.
- Strategic Acquisition: TuHURA's merger with Kineta Inc. has brought TBS-2025 into its portfolio, demonstrating its expansion strategy in cancer immunotherapy aimed at addressing primary and acquired resistance issues in cancer treatments.
See More
TuHURA Files IND for TBS-2025 in AML Treatment
- New Drug Application: TuHURA Biosciences has filed an Investigational New Drug (IND) application with the FDA for TBS-2025, aimed at treating mutNPM1 relapsed/refractory Acute Myeloid Leukemia (AML) in combination with a menin inhibitor, potentially improving patient response rates.
- Clinical Trial Design: The company plans to initiate a Phase 2 clinical trial in menin inhibitor-naïve patients in early Q2 2026, utilizing a Simon 2 stage design, with preliminary results expected in Q3 2026, demonstrating ongoing commitment to this therapeutic area.
- Scientific Rationale: Research indicates that mutations like mutNPM1 may drive VISTA expression on leukemic cells, leading to poor treatment responses; TuHURA believes that adding TBS-2025 could significantly enhance both the CR/CRh rates and their duration, addressing unmet medical needs.
- Safety Assessment: TBS-2025 has shown a favorable safety profile in early trials at a maximum dose of 1,000mg every two weeks, with the optimal Phase 2 dose projected at 750mg every three weeks, laying a solid foundation for further clinical development.
See More
TuHURA Biosciences to Present at Oppenheimer Healthcare Conference
- Presentation Schedule: TuHURA Biosciences' CEO James Bianco will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 3:20 PM ET, showcasing the company's advancements in cancer immunotherapy.
- Clinical Trial Progress: TuHURA is conducting a Phase 3 registration trial for IFx-2.0 as an adjunct therapy to Keytruda®, aimed at overcoming primary resistance to checkpoint inhibitors, which is expected to significantly enhance treatment outcomes for patients with advanced or metastatic Merkel Cell Carcinoma.
- Technological Innovation: The company is also developing first-in-class bi-specific antibody drug conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment, thereby preventing T cell exhaustion and acquired resistance to checkpoint inhibitors, highlighting its cutting-edge position in immuno-oncology.
- Acquisition and Development: TuHURA acquired TBS-2025, a VISTA inhibiting mAb, through its merger with Kineta Inc. on June 30, 2025, which has now entered Phase 2 development, further strengthening the company's product pipeline and market competitiveness.
See More
TuHURA Biosciences Regains Nasdaq Compliance
- Compliance Regained: TuHURA Biosciences announced on February 26, 2026, that it has regained compliance with Nasdaq's listing standards, with its stock closing above $1.00 for the last 11 consecutive trading days, enhancing the company's market stability and investor confidence.
- Clinical Trial Progress: The company is advancing its Phase 3 accelerated approval trial for IFX-2.0 targeting front-line Merkel Cell Carcinoma, demonstrating its ongoing innovation in the cancer immunotherapy sector.
- New Drug Development: TuHURA is preparing for the initiation of a Phase 2 study for TBS-2025, a VISTA inhibiting antibody aimed at treating relapsed/refractory NPM1 mutated AML, further enriching its product pipeline.
- Technological Innovation: The company is also developing first-in-class bi-specific antibody drug conjugates leveraging Delta Opioid Receptor technology to inhibit immune-suppressing effects in the tumor microenvironment, thereby enhancing the efficacy of immunotherapy.
See More
TuHURA Biosciences Regains Nasdaq Compliance
- Compliance Regained: TuHURA Biosciences announced on February 26, 2026, that it has regained compliance with Nasdaq's minimum bid price requirement of $1.00, as the company's stock price remained above this threshold for 11 consecutive business days, thereby alleviating compliance concerns and boosting investor confidence.
- Clinical Trial Progress: The company is advancing its Phase 3 accelerated approval trial for IFX-2.0 in front-line Merkel Cell Carcinoma, indicating ongoing commitment to cancer immunotherapy and potential market opportunities.
- New Drug Development: TuHURA is preparing to initiate a Phase 2 study for TBS-2025 targeting relapsed/refractory NPM1 mutated AML, further diversifying its product pipeline and enhancing competitive positioning in the oncology market.
- Technological Innovation: The company is developing first-in-class bi-specific antibody drug conjugates aimed at inhibiting immune-suppressing cells in the tumor microenvironment to prevent T cell exhaustion and acquired resistance, showcasing its innovative potential in immuno-oncology.
See More
TuHURA Biosciences to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: TuHURA's CEO, James Bianco, will participate in the Citizens Life Science Conference on March 10, 2026, where he will present online, likely increasing investor interest and enhancing the company's visibility.
- One-on-One Investor Meetings: At the Leerink Global Healthcare Conference on March 11, 2026, TuHURA will offer one-on-one meetings with investors, which will help strengthen relationships with potential investors and drive funding opportunities.
- Clinical Trial Progress: TuHURA is conducting a Phase 3 registration trial for IFx-2.0 as an adjunct therapy to Keytruda, aimed at overcoming primary resistance to cancer immunotherapy, which, if successful, will significantly enhance the company's competitive position in the oncology market.
- Technological Innovation and Acquisition: TuHURA acquired TBS-2025 through its merger with Kineta Inc., which is moving into Phase 2 development, showcasing the company's innovative capabilities and potential for market expansion in immuno-oncology.
See More
TuHURA Biosciences to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: TuHURA Biosciences CEO James Bianco will participate in the Citizens Life Science Conference on March 10, 2026, and the Leerink Global Healthcare Conference on March 11, showcasing the company's advancements in cancer immunotherapy, which is expected to attract potential investors' interest.
- Clinical Trial Progress: TuHURA is conducting a Phase 3 registration trial for IFx-2.0, designed to be used in conjunction with Keytruda® for advanced or metastatic Merkel Cell Carcinoma, and if successful, it will significantly enhance the company's competitiveness in the cancer treatment market.
- Technological Innovation: The company is advancing TBS-2025, an antibody drug targeting mutNPM1 relapsed/refractory acute myeloid leukemia, into Phase 2 development, which, if successful, will further enrich TuHURA's product pipeline and strengthen its market position.
- Strategic Acquisition: TuHURA's merger with Kineta Inc. has brought TBS-2025 into its portfolio, demonstrating its expansion strategy in cancer immunotherapy aimed at addressing primary and acquired resistance issues in cancer treatments.
See More
TuHURA Files IND for TBS-2025 in AML Treatment
- New Drug Application: TuHURA Biosciences has filed an Investigational New Drug (IND) application with the FDA for TBS-2025, aimed at treating mutNPM1 relapsed/refractory Acute Myeloid Leukemia (AML) in combination with a menin inhibitor, potentially improving patient response rates.
- Clinical Trial Design: The company plans to initiate a Phase 2 clinical trial in menin inhibitor-naïve patients in early Q2 2026, utilizing a Simon 2 stage design, with preliminary results expected in Q3 2026, demonstrating ongoing commitment to this therapeutic area.
- Scientific Rationale: Research indicates that mutations like mutNPM1 may drive VISTA expression on leukemic cells, leading to poor treatment responses; TuHURA believes that adding TBS-2025 could significantly enhance both the CR/CRh rates and their duration, addressing unmet medical needs.
- Safety Assessment: TBS-2025 has shown a favorable safety profile in early trials at a maximum dose of 1,000mg every two weeks, with the optimal Phase 2 dose projected at 750mg every three weeks, laying a solid foundation for further clinical development.
See More
TuHURA Biosciences to Present at Oppenheimer Healthcare Conference
- Presentation Schedule: TuHURA Biosciences' CEO James Bianco will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 3:20 PM ET, showcasing the company's advancements in cancer immunotherapy.
- Clinical Trial Progress: TuHURA is conducting a Phase 3 registration trial for IFx-2.0 as an adjunct therapy to Keytruda®, aimed at overcoming primary resistance to checkpoint inhibitors, which is expected to significantly enhance treatment outcomes for patients with advanced or metastatic Merkel Cell Carcinoma.
- Technological Innovation: The company is also developing first-in-class bi-specific antibody drug conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment, thereby preventing T cell exhaustion and acquired resistance to checkpoint inhibitors, highlighting its cutting-edge position in immuno-oncology.
- Acquisition and Development: TuHURA acquired TBS-2025, a VISTA inhibiting mAb, through its merger with Kineta Inc. on June 30, 2025, which has now entered Phase 2 development, further strengthening the company's product pipeline and market competitiveness.
See More
